Zopolrestat
Zopolrestat has been studied in 1 paper since 2022: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Jul 28, 2022: “Aldose reductase promotes diet-induced obesity via induction of senescence in subcutaneous adipose tissue”.
See all 1 papers on zopolrestat
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: National Heart, Lung, and Blood Institute and 1 more
- Animals1
What did studies of zopolrestat find?
3Studies of zopolrestat measured 3 outcomes; the most studied are lipid and ceramide metabolism (1 study), cellular senescence (1) and obesity (1).
Lipid and ceramide metabolism
upin mice1
1 study
Lipid and ceramide metabolism
upin mice1
Zopolrestat activates lipid and ceramide metabolism in mice (high-fat diet).
“and increased lipolysis”
Animalshigh-fat diet
Obesity (Silver Spring, Md.)
Cellular senescence
downin mice1
1 study
Cellular senescence
downin mice1
Zopolrestat inhibits cellular senescence in mice (high-fat diet).
“attenuated markers of adipose tissue senescence”
Animalshigh-fat diet
Obesity (Silver Spring, Md.)
Obesity
downin mice1
1 study
Obesity
downin mice1
Zopolrestat protects against obesity in mice (high-fat-diet-induced obesity).
“Genetic deletion of Akr1b3 or pharmacological blockade of AKRIB3 with zopolrestat reduced high-fat-diet-induced obesity”
Animalshigh-fat-diet-induced obesity
Obesity (Silver Spring, Md.)